Cas9 Stable Cell Line - LLC

Lewis lung cancer (LLC) cell lines, derived from spontaneous lung cancer in C57BL/6 mice, were first established in 1951. As a widely used mouse model, LLC cells exhibit aggressive metastatic characteristics, particularly readily metastasizing to the lungs, thus possessing invaluable significance in studying cancer biology, tumor progression, and metastasis mechanisms. The Cas9 Stable Cell Line - LLC is constructed by stably integrating the CRISPR-associated protein 9 (Cas9) endonuclease into the LLC genome. This engineered cell line maintains stable Cas9 expression without selection pressure during passage culture, thus possessing robust and durable gene-editing capabilities. This cell line retains characteristics of parental LLC cells, including epithelial-like morphology, rapid proliferation, and tumorigenicity in immunocompetent mice, while also possessing precise genomic manipulation capabilities.

The Cas9 Stable Cell Line - LLC is a powerful platform for a variety of oncology research applications. Its primary function is to perform high-throughput functional genomics screening using mixed sgRNA libraries to identify cancer driver genes, tumor suppressor genes, and metastasis regulators. Researchers can knock out specific targets, such as PD-L1, VEGF, or immune checkpoint molecules, to study their roles in tumor immune escape or angiogenesis. This cell line also supports in vivo CRISPR studies, allowing the establishment of tumor models in syngeneic mice and targeted gene editing during tumor progression to mimic therapeutic interventions. Furthermore, it supports drug development by constructing syngeneic cell models with precise mutations to evaluate the efficacy of compounds against specific gene alterations.